Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
Methods of using a compound, its pharmaceutically acceptable salts, and/or its pro-drug esters, in isolated form, to treat cancer, and methods for isolating, for formulating, and for administering the compound, salt, and/or pro-drug ester as an antitumor agent, wherein the compound, salt, or pro-drug ester has the following structure: wherein: R 1 , R 2 , R 5 , R 7 , and R 8 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C 1 -C 24 alkyl, unsaturated C 1 -C 24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, substituted nitro, phenyl, and substituted phenyl groups, R 3 , R 4 , and R 6 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C 1 -C 12 alkyl, unsaturated C 1 -C 12 alkenyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted nitro groups, X 1 and X 2 are separately selected from the group consisting of an oxygen atom, and a sulfur atom, and the dashed bond represents a bond selected from the group consisting of a carbon-carbon single bond and a carbon-carbon double bond. Most preferably, R 3 and R 4 are hydrogen, and each are involved in hydrogen bonds, and/or the dashed bond is a double bond, such that the chemical backbone of the compound substantially retains a substantially planar conformation.
1. A method of treating at least one fungal infection in a mammal afflicted with at least one fungal infection which comprises administering an antifungally effective amount of a compound sufficient for such treating or preventing, and wherein the compound has the following structure:
wherein:
R 1 , R 2 , R 5 , R 7 , and R 8 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C 1 -C 24 alkyl, unsaturated C 1 -C 24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, substituted nitro, phenyl, and substituted phenyl groups,
R 3 , R 4 , and R 6 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C 1 -C 12 alkyl, unsaturated C 1 -C 12 alkenyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted nitro groups,
X 1 and X 2 are separately selected from the group consisting of an oxygen atom, and a sulfur atom, and
the dashed bond represents a bond selected from the group consisting of a carbon-carbon single bond and a carbon-carbon double bond.
2. The method of claim 1 , wherein the fungal infection is selected from the group consisting of an Aspergillosis infection, blastomycosis infection, Candidiasis infection, Coccidioidomycosis infection, Cryptococcosis infection, Histopolasmosis infection, Paracoccidioidomycosis, Sporotrichosisand, and Mucormycosis infection.
3. The method of claim 2 , wherein the Aspergillosis infection is invasive pulmonary aspergillosis.
4. The method of claim 2 , wherein the Mucormycosis infection is craniofacial mucormycosis or pulmonary mucormycosis.
5. The method of claim 2 , wherein the Candidiasis infection is retrograde candidiasis of the urinary tract.
6. A pharmaceutical composition for treating fungal infection comprising an antifungally effective amount of a pharmaceutically acceptable carrier and a compound having the structure:
wherein:
R 1 , R 2 , R 5 , R 7 , and R 8 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C 1 -C 24 alkyl, unsaturated C 1 -C 24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, substituted nitro, phenyl, and substituted phenyl groups,
R 3 , R 4 , and R 6 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C 1 -C 12 alkyl, unsaturated C 1 -C 12 alkenyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted nitro groups,
X 1 and X 2 are separately selected from the group consisting of an oxygen atom, and a sulfur atom, and
the dashed bond represents a bond selected from the group consisting of a carbon-carbon single bond and a carbon-carbon double bond.
7. The composition of claim 6 , wherein the fungal infection is selected from the group consisting of an Aspergillosis infection, blastomycosis infection, Candidiasis infection, Coccidioidomycosis infection, Cryptococcosis infection, Histopolasmosis infection, Paracoccidioidomycosis, Sporotrichosisand, and Mucormycosis infection.
8. The composition of claim 7 , wherein the Aspergillosis infection is invasive pulmonary aspergillosis.
9. The composition of claim 7 , wherein the Mucormycosis infection is craniofacial mucormycosis or pulmonary mucormycosis.
10. The composition of claim 7 , wherein the Candidiasis infection is retrograde candidiasis of the urinary tract.